LP-10
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hemorrhagic Cystitis
Conditions
Hemorrhagic Cystitis
Trial Timeline
Oct 1, 2020 → Sep 29, 2023
NCT ID
NCT03129126About LP-10
LP-10 is a phase 2 stage product being developed by Lipella Pharmaceuticals for Hemorrhagic Cystitis. The current trial status is completed. This product is registered under clinical trial identifier NCT03129126. Target conditions include Hemorrhagic Cystitis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03129126 | Phase 2 | Completed |
Competing Products
10 competing products in Hemorrhagic Cystitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| BAF312 solution + Matching Placebo for BAF312 solution + BAF312 tablet + Matching Placebo for BAF312 tablet | Novartis | Phase 2 | 52 |
| ALN-6400 + Placebo | Alnylam Pharmaceuticals | Phase 1/2 | 38 |
| AVI-7537 | United Therapeutics | Phase 1 | 30 |
| AVI-7288 | United Therapeutics | Phase 1 | 30 |
| Placebo + AVI-6002 | United Therapeutics | Phase 1 | 30 |
| AVI-6003 + Placebo | United Therapeutics | Phase 1 | 30 |
| Ad26.ZEBOV + MVA-BN-Filo | Bavarian Nordic | Phase 3 | 74 |
| Tranexamic acid first, than placebo + First placebo, than Tranexamic acid. | Baxter | Phase 3 | 74 |
| Ribavirin (Virazole) Injection | Bausch Health | Phase 2 | 47 |
| BGE-117, 4mg + BGE-117, 12mg | BioAge Labs | Phase 2 | 47 |